Koide K, Sano M, Takeda F, Momose T, Koshikawa S, Akizawa T
Teikyo University Ichihara Hospital, Chiba, Japan.
Biomater Artif Cells Immobilization Biotechnol. 1991;19(1):147-66. doi: 10.3109/10731199109117822.
In order to examine the effect on the progression of chronic renal failure (CRF), we have applied an oral adsorbent (AST-120) composed of spherical porous carbon particles to patients with chronic renal failure undergoing conservative therapy. Its effect was observed in improvement of uremic symptoms, improvement of slope in linear regression of reciprocal of serum creatinine vs. time plots and delayed initiation of hemodialysis, compared to control patients, together with reduced uremic peak 2a in HPLC analysis of serum and lower levels of beta 2 microglobulin in AST-120 group than in control. The improvements of uremic symptoms, creatinine and 2a levels were confirmed in double blind study where background of patients were evenly randomized between AST-120 and placebo groups and no improvement was observed in placebo group. The result leads us to conclude that the oral adsorbent therapy is expected as an useful therapy for retardation of progression of CRF.
为了研究对慢性肾衰竭（CRF）进展的影响，我们将一种由球形多孔碳颗粒组成的口服吸附剂（AST - 120）应用于接受保守治疗的慢性肾衰竭患者。与对照组患者相比，观察到其在改善尿毒症症状、改善血清肌酐倒数与时间曲线线性回归的斜率以及延迟血液透析开始时间方面的效果，同时在血清的高效液相色谱分析中尿毒症峰2a降低，AST - 120组的β2微球蛋白水平低于对照组。在双盲研究中证实了尿毒症症状、肌酐和2a水平的改善，该研究中患者背景在AST - 120组和安慰剂组之间均匀随机分配，且安慰剂组未观察到改善。结果使我们得出结论，口服吸附剂疗法有望成为延缓CRF进展的有效疗法。
